What follows is about presentation, not about companies. Every pattern below is legal, widespread, and in most cases unremarkable on its own. The reason to know them is arithmetic: each one can make two prices look comparable when they are measuring different things. Treat each as a question to settle rather than a verdict to reach, and use the price board to see what a given seller actually publishes.
A headline figure is a rate, not a bill
The most common shape in this category is a number that is true for one month. It may be an opening rate, a promo code, a per-month figure that only applies on a prepaid term, or the price of the first rung of the dose ladder. None of those is dishonest. All of them describe something other than what the fourth charge will be.
The Federal Trade Commission has set out what a buyer is entitled to see before agreeing to a recurring charge. Its enforcement statement on negative-option marketing lists the minimum disclosures. Those include that charges will be made, that they may rise once a trial period ends, and that they recur unless stopped. They also include each deadline for stopping them, the amount or range, and the dates each charge will be submitted.[1]
That converts neatly into one question. What is the charge in month four, on what date, and where on the page does it say so? A seller that answers in writing has given you a number you can compare. A seller that repeats the headline has not.
The fee that sits outside the headline
Some prices in this market cover the medication and bill a membership separately. Others cover a membership, a consultation and coaching, and leave the medication to be billed elsewhere. Both structures are ordinary and both are disclosed somewhere. The problem arrives when a figure of the first kind is set beside a figure of the second kind.
The settling question is narrow: does this number include the drug, the clinician, the shipping and the injection supplies, or does it include some of them? Until that is answered, two monthly figures are not two prices for the same thing.
An anchor that has never moved
A struck-through figure invites you to read the lower one as a saving. It only means that if the higher figure was ever charged. A discount that has been running continuously since a site launched is a price, presented in the shape of a reduction.
This is a pricing style rather than a scandal, and the practical response is simply to ignore the anchor. Compare the number you would pay against the number you would pay elsewhere, and let the struck figure carry no weight in the comparison at all.
A promotion with a date already behind it
An offer that expired last quarter and still sits on the page is rarely a trick. It is usually evidence that nobody is maintaining the page, and that is the useful reading. A page nobody has updated may also be carrying a stale price, a stale dose ladder or a stale state list.
So the finding is not about the coupon. It is that the page cannot be assumed current, which makes a written confirmation of today’s price worth more than anything printed on it.
A word where a milligram should be
Plans sold as a microdose, a starter protocol or an entry tier are named for a price band rather than a quantity. The vocabulary carries no dose, so two plans described with the same word can deliver substantially different amounts of drug — the point argued at length in the article on that word.
Presenting such a plan as equivalent to a standard one extends trial results past what they measured. The related pattern is a price that holds only at the bottom of the ladder, and the ladder is designed to be climbed. What that climb costs is worked through in the titration article. Sellers that hold one price across every dose remove the variable entirely.
No list of states
Telehealth prescribing is licensed state by state, so where a service can legally reach you is a fact with a definite answer. Publishing it costs nothing. A site that does not is asking you to discover the answer at checkout, or after an intake form, which is a poor use of your time rather than a hazard.
Coverage in this category varies widely, and a good many sellers publish no list at all. Where a company does publish one, it is recorded in the seller write-ups alongside the rest of what the company states about itself.
No pharmacy named
A compounded product is prepared by a pharmacy, and the seller taking the order is usually not that pharmacy. The FDA has noted that consumers buying compounded drugs through online pharmacies and telehealth platforms may not know the identity of the compounder that produced the drug.[2]
Silence here is not evidence of a poor pharmacy. It is the absence of the one fact that would let anyone check, and it sits alongside the other facts a compounded vial does not print — set out in the article on contents. Asking is free, and the answer, or the refusal, is informative either way.
What none of this proves
Every pattern above describes how information is presented. None of them describes what is in the vial, who prepared it, or whether a particular company will serve you well. A seller displaying several may be entirely sound. A seller displaying none has not thereby been shown to be anything.
That asymmetry is the part worth holding onto, because the natural way to misread a list like this is as a screening tool. It is not one. It is a set of questions that turn a marketing page into checkable claims, and the answers still have to be weighed.
One more thing belongs on a page like this. GLP Loss earns a commission on links to a share of the companies it covers, and these seven patterns are applied to every seller alike, partner or not. What that relationship is and where it appears is set out in the disclosures, and how a position on a board is produced is set out in the methodology.